ONCT
Oncternal Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website oncternal.com
- Employees(FY) 30
- ISIN US68236P2065
Performance
+0.29%
1W
-0.35%
1M
+2.85%
3M
+35.27%
6M
-19.25%
YTD
+37.03%
1Y
Profile
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Technical Analysis of ONCT 2024-05-10
Overview:
In analyzing the technical indicators for ONCT over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key factors, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-10 00:40
- 2024-05-09 08:58
- 2024-05-09 05:20
- 2024-05-09 04:01
- 2024-05-08 00:00
- 2024-05-02 04:05
- 2024-04-30 21:00
- 2024-04-24 22:02
- 2024-04-17 21:00
- 2024-04-14 00:51
5 Buy-Rated Stocks with Latest Insider Purchases(Insidermonkey)
- 2024-04-10 04:42
10 Underperforming Stocks Insiders are Buying(Insidermonkey)
- 2024-03-14 21:00
- 2024-03-07 21:26
- 2024-03-07 08:54
- 2024-03-07 08:54
- 2024-03-07 03:01
- 2024-02-29 03:05
- 2024-02-06 03:30
- 2024-01-31 20:00
- 2024-01-07 20:00
- 2024-01-03 20:00
Oncternal Therapeutics Announces Reverse Stock Split(Globenewswire)
- 2024-01-01 20:00
- 2023-12-27 22:04
- 2023-12-25 20:00
- 2023-11-10 22:06
- 2023-11-09 03:01
- 2023-11-02 04:05
- 2023-10-25 21:00
- 2023-10-24 21:00
- 2023-10-05 04:01
Page 1 of 4
previousnext